Concepedia

Author

Morris Sherman

University of TorontoORCID

Also Known As

Florin Selaru, Fried, Michael W., Laurie Powell, M I Sherman, M SHERMAN, M Sherman, M. I. Sherman, M. SHERMAN, M. Sherman, M.S. Sherman

341

Publications

44.8K

Citations

74

H-Index

137

Concepts

All Affiliations

University of TorontoUniversity Health NetworkToronto General HospitalUniversity of CalgaryUniversity of Alberta
MS

About

Morris Sherman is an author at University of Toronto specializing in medicine, hepatology, and hepatocellular carcinoma.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

35

64

10.3K

2

Health Sciences

15

15

2K

3

Public Health

6

6

516

4

Education

1

1

11

5

Engineering

1

1

109

Morris Sherman

×

127

Publications

34K

Citations

62

H-Index

YearCitations

Management of Hepatocellular Carcinoma: An Update Δσ

Jordi Bruix, Morris Sherman

Hepatology

2011

8.1K

Management of Hepatocellular Carcinoma *

Jordi Bruix, Morris Sherman

Hepatology

2005

5.9K

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

Jordi Bruix, Morris Sherman, Josep M. Llovet,

Journal of Hepatology

2001

4.1K

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study

Joong‐Won Park, Minshan Chen, M. Colombo,

Liver International

2015

1.2K

Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma

Mariana Capurro, Ian R. Wanless, Morris Sherman,

Gastroenterology

2003

893

Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma

Alexis Bujold, Christine Massey, John J. Kim,

Journal of Clinical Oncology

2013

820

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix, Jean‐Luc Raoul, Morris Sherman,

Journal of Hepatology

2012

819

Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

M. Hawkins, Gina Lockwood, John J. Kim,

Journal of Clinical Oncology

2008

596

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul,

Journal of Clinical Oncology

2013

592

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath,

The Lancet Oncology

2012

549

Page 1